Physician profile
John Wenceslao
NPI 1740203868
$29,554.32
in general payments reported to CMS, 2019-2025
69 companies · $3,690 in 2025
The $3,690 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,463 · 2020: $3,203 · 2021: $5,198 · 2022: $4,020 · 2023: $4,062 · 2024: $3,917 · 2025: $3,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,469.87 |
| Education | $200.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,192.48 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $2,761.99 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $2,585.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,889.85 | 2019-2025 | Spravato |
| Novo Nordisk INC | $1,823.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,366.42 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $1,318.81 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,087.33 | 2019-2025 | |
| Lilly USA, LLC | $1,036.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $1,013.32 | 2019-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $973.33 | 2019-2025 | Eliquis |
| Amgen INC. | $950.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $850.02 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $843.10 | 2019-2025 | |
| Esperion Therapeutics, INC. | $514.46 | 2020-2025 | Nexletol |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wenceslao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.